Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene.

Oxidative stress could be involved in the pathophysiology of schizophrenia, a major psychiatric disorder. Glutathione (GSH), a redox regulator, is decreased in patients' cerebrospinal fluid and prefrontal cortex. The gene of the key GSH-synthesizing enzyme, glutamate cysteine ligase modifier (GCLM) subunit, is strongly associated with schizophrenia in two case-control studies and in one family study. GCLM gene expression is decreased in patients' fibroblasts. Thus, GSH metabolism dysfunction is proposed as one of the vulnerability factors for schizophrenia.

[1]  M. Cuénod,et al.  Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia , 2006, Neuroscience.

[2]  R. Kraftsik,et al.  Glutathione deficit during development induces anomalies in the rat anterior cingulate GABAergic neurons: Relevance to schizophrenia , 2006, Neurobiology of Disease.

[3]  Ravinder Reddy,et al.  Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.

[4]  Naoshi Kaneko,et al.  Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. , 2005, American journal of human genetics.

[5]  D. Nebert,et al.  Glutamate Cysteine Ligase Catalysis , 2005, Journal of Biological Chemistry.

[6]  Andrew L. Lemire,et al.  Deficient Hippocampal Neuron Expression of Proteasome, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts , 2005, Biological Psychiatry.

[7]  David A Lewis,et al.  Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. , 2005, The American journal of psychiatry.

[8]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[9]  M. Cuénod,et al.  An animal model with relevance to schizophrenia: sex-dependent cognitive deficits in osteogenic disorder-Shionogi rats induced by glutathione synthesis and dopamine uptake inhibition during development , 2004, Neuroscience.

[10]  A. Serretti,et al.  Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population , 2004, Psychiatric genetics.

[11]  T. Shinkai,et al.  No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia , 2004, Psychiatric genetics.

[12]  M. Cuénod,et al.  Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia , 2004, Neurobiology of Disease.

[13]  M. Owen,et al.  A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress , 2003, Schizophrenia Research.

[14]  M. Cuénod,et al.  Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia , 2003, Schizophrenia Research.

[15]  A. Serretti,et al.  Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  Paul J. Harrison,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Genes for Schizophrenia? Recent Findings and Their Pathophysiological Implications , 2022 .

[17]  D. Nebert,et al.  Initial Characterization of the Glutamate-Cysteine Ligase Modifier Subunit Gclm(−/−) Knockout Mouse , 2002, The Journal of Biological Chemistry.

[18]  K. Kugiyama,et al.  Polymorphism in the 5'-flanking region of human glutamate-cysteine ligase modifier subunit gene is associated with myocardial infarction. , 2002, Circulation.

[19]  Marc Zabeau,et al.  A strategy for the rapid discovery of disease markers using the MassARRAY system. , 2002, BioTechniques.

[20]  S. Harada,et al.  Glutathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. , 2001, Biochemical and biophysical research communications.

[21]  D. Housman,et al.  Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes , 2000, Molecular Psychiatry.

[22]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[23]  S. Lipton,et al.  Redox modulation of the NMDA receptor , 2000, Cellular and Molecular Life Sciences CMLS.

[24]  M. Tsuang.  Schizophrenia: genes and environment , 2000, Biological Psychiatry.

[25]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[26]  T. Hastings,et al.  Role of Endogenous Glutathione in the Oxidation of Dopamine , 1998, Journal of neurochemistry.

[27]  S. Mukherjee,et al.  Free radical pathology and antioxidant defense in schizophrenia: a review , 1996, Schizophrenia Research.

[28]  C. Disteche,et al.  Mapping of the glutamate-cysteine ligase catalytic subunit gene (GLCLC) to human chromosome 6p12 and mouse chromosome 9D-E and of the regulatory subunit gene (GLCLR) to human chromosome 1p21-p22 and mouse chromosome 3H1-3. , 1995, Genomics.

[29]  F. Holsboer,et al.  γ‐Glutamylglutamine and Taurine Concentrations Are Decreased in the Cerebrospinal Fluid of Drug‐Naive Patients with Schizophrenic Disorders , 1995, Journal of neurochemistry.

[30]  J. Nurnberger,et al.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. , 1994, Archives of general psychiatry.

[31]  H. Monyer,et al.  NMDA receptor channels: Subunit-specific potentiation by reducing agents , 1994, Neuron.

[32]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[33]  M. Anderson,et al.  Amino acid sequence and function of the light subunit of rat kidney gamma-glutamylcysteine synthetase. , 1993, The Journal of biological chemistry.

[34]  M. Anderson,et al.  Catalytic and regulatory properties of the heavy subunit of rat kidney gamma-glutamylcysteine synthetase. , 1993, The Journal of biological chemistry.

[35]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[36]  J. Coyle,et al.  NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. , 2004, International review of neurobiology.

[37]  H. Herken,et al.  Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.